Your briefing

UBS Reaffirms Buy on Elevance Despite Adjusted 2025 Earnings Outlook
Finance 6 days ago
UBS Reaffirms Buy on Elevance Despite Adjusted 2025 Earnings Outlook
Full Coverage

ASML Growth Outlook Trimmed by Bernstein Over EUV Concerns
Finance 6 days ago
ASML Growth Outlook Trimmed by Bernstein Over EUV Concerns
Full Coverage

Progressive EPS Outlook Raised; KBW Keeps Market Perform Rating
Finance 6 days ago
Progressive EPS Outlook Raised; KBW Keeps Market Perform Rating
Full Coverage

UBS Reiterates Price Target for PayPal Amid New TPV Category Breakdown
Finance 6 days ago
UBS Reiterates Price Target for PayPal Amid New TPV Category Breakdown
Full Coverage

Trending

1. Joann's closing
2. Texas Tech basketball
3. UNC basketball
4. Monster Hunter Wilds
5. Ketamine
6. Macron
7. UPMC Memorial shooting
8. Eagles
9. Hims stock
10. Joel Embiid

Popular News

BrightGene präsentiert positive Phase-2-Daten für den Dual-G...
1 week ago
BrightGene präsentiert positive Phase-2-Daten für den Dual-GLP-1R/GIPR-Agonisten zur Gewichtsregulation und Behandlung von Typ-2-Diabetes sowie präklinische Daten für ein neues Amylin-Analogon bei den 85 Wissenschaftlichen Sitzungen der American Diabetes Association

The mortgage market hopes for rate cuts amid war moves
1 week ago
The mortgage market hopes for rate cuts amid war moves

Ukraine returns bodies of 3 Russian soldiers repatriated as ...
1 week ago
Ukraine returns bodies of 3 Russian soldiers repatriated as remains of Ukrainians, Interior Ministry says

BrightGene presenteert positieve fase 2 gegevens voor de dua...
1 week ago
BrightGene presenteert positieve fase 2 gegevens voor de duale GLP-1R/GIPR agonist voor gewichtsbeheersing en type 2 diabetes, en preklinische gegevens voor een nieuw amylin-analoog tijdens de 85e wetenschappelijke sessies van de American Diabetes Association

BrightGene présente des données positives de phase 2 pour so...
1 week ago
BrightGene présente des données positives de phase 2 pour son agoniste double GLP-1R/GIPR dans la gestion du poids et le diabète de type 2, ainsi que des données précliniques pour un nouvel analogue de l'amylin, lors de la 85 e édition des Sessions Scientifiques de l'American Diabetes Association
About Us · Contact Us · Terms & Conditions · Help · Privacy ·

© Latest News Search Engine - Global and Local Breaking News 2025. All rights are reserved